Details of Disease

General Information of Disease (ID: DIS59MOU)

Disease Name Malignant thymoma
Synonyms
THYC; thymoma, malignant (morphologic abnormality); thymoma type C; thymoma, malignant; thymoma, type C (morphologic abnormality); thymus carcinoma; thymic carcinoma; thymic carcinoma excluding well differentiated thymic carcinoma; malignant thymoma; type C thymoma; carcinoma of thymus; thymoma, type C; thymic carcinoma (excluding well differentiated thymic carcinoma)
Disease Class 2C27: Thymoma
Definition Thymic carcinoma (TC) is a type of thymic epithelial neoplasm characterized by a high malignant potential.
Disease Hierarchy
DIS0TBWN: Thymus cancer
DISWIT0F: Thymic epithelial neoplasm
DISH9F1N: Carcinoma
DIS59MOU: Malignant thymoma
ICD Code
ICD-11
ICD-11: 2C27.2
Expand ICD-11
'2C27.2
Disease Identifiers
MONDO ID
MONDO_0006451
MESH ID
D013945
UMLS CUI
C0205969
MedGen ID
60049
Orphanet ID
99868
SNOMED CT ID
128717008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 DMTM82B Patented NA [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 8 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CD274 TT8ZLTI Limited Biomarker [2]
BAP1 TT47RXJ Strong Biomarker [3]
CDKN2A TTFTWQ8 Strong Genetic Variation [4]
GGH TTZJRL0 Strong Biomarker [5]
HRAS TT28ZON Strong Genetic Variation [6]
PBRM1 TTH8ZRL Strong Biomarker [3]
PTGES2 TTWU04I Strong Biomarker [7]
TP53 TT12KOD Strong Biomarker [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTT(s)
This Disease Is Related to 9 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ABCE1 OTH19LOA Strong Biomarker [9]
CLIC2 OTDBURM4 Strong Biomarker [9]
CYLD OT37FKH0 Strong Biomarker [3]
GNG4 OTOXNDI9 Strong Posttranslational Modification [10]
GTF2I OTUYL1TQ Strong Genetic Variation [11]
HOXD9 OTZ4GVR1 Strong Biomarker [10]
NUTM1 OTONYC08 Strong Altered Expression [12]
SALL3 OTJ2LZKQ Strong Posttranslational Modification [10]
TAB1 OTPM6F85 Strong Biomarker [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
2 The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma.Cancer Med. 2019 Jan;8(1):216-226. doi: 10.1002/cam4.1943. Epub 2019 Jan 1.
3 A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.Nat Genet. 2014 Aug;46(8):844-9. doi: 10.1038/ng.3016. Epub 2014 Jun 29.
4 Loss of p16(INK4A) Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas.J Thorac Oncol. 2017 May;12(5):860-871. doi: 10.1016/j.jtho.2017.01.028. Epub 2017 Feb 5.
5 Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma.J Cardiothorac Surg. 2016 May 26;11(1):85. doi: 10.1186/s13019-016-0468-1.
6 Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.Clin Cancer Res. 2009 Nov 15;15(22):6790-9. doi: 10.1158/1078-0432.CCR-09-0644. Epub 2009 Oct 27.
7 COX-2 upregulation in thymomas and thymic carcinomas.Int J Cancer. 2006 Nov 1;119(9):2063-70. doi: 10.1002/ijc.22078.
8 A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.Histopathology. 2019 Nov;75(5):755-766. doi: 10.1111/his.13936. Epub 2019 Oct 3.
9 Diagnosis of thymic epithelial tumor subtypes by a quantitative proteomic approach.Analyst. 2018 May 29;143(11):2491-2500. doi: 10.1039/c8an00218e.
10 DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma.Int J Oncol. 2020 Jan;56(1):315-326. doi: 10.3892/ijo.2019.4915. Epub 2019 Nov 18.
11 The genomic and epigenomic landscape in thymic carcinoma.Carcinogenesis. 2017 Oct 26;38(11):1084-1091. doi: 10.1093/carcin/bgx094.
12 NUT rearrangement is uncommon in human thymic epithelial tumors.J Thorac Oncol. 2012 Apr;7(4):744-50. doi: 10.1097/JTO.0b013e3182460f8f.
13 Povidone-iodine results in rapid killing of thymic epithelial tumour cells through cellular fixation?"Lee HS. Lo EM